Refining the young mania rating scale: Accelerating development of psychopathology measures joint ISCTM/ECNP bipolar working group consensus.

Manpreet K Singh¹, Gary Sachs², Jenicka Engler³, Ole Andreasen⁴, Montserrat Cosials-Lopez⁵, Rasmus Licht⁶, Mirko Manchia⁷, Luca Pani⁸, Andreas Reif⁹, Eva Reininghaus¹⁰, Erin Tomaszewski¹¹, Eduard Vieta¹², Robert C Young¹³

¹University of California Davis School of Medicine, Sacramento, CA, USA. Electronic address: mpksingh@health.ucdavis.edu.

²Signant Health and Massachusetts General Hospital, USA.

³Cronos, an IQVIA business, USA.

⁴Center for Precision Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Norway.

⁵Experts by Experience, Barcelona, Spain.

⁶Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark.

⁷Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari and Unit of Clinical Psychiatry, Department of Medical Specialties, University Hospital Agency of Cagliari, Cagliari, Italy; Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada.

⁸Department of Psychiatry and Behavioral Sciences, Leonard M. Miller School of Medicine University of Miami, Miami, USA; Dept. of Biomedical, Metabolic and Neural Sciences University of Modena and Reggio Emilia, Modena, Italy.

⁹Department of Psychiatry, Psychosomatic Medicine and Psychotherapy at the University Hospital Frankfurt (Goethe University), Germany.

¹⁰Medical University of Graz, Clinical Division of Psychiatry and Psychotherapeutic Medicine, Austria.

¹¹Abbvie Inc., USA.

¹²Institute of Neuroscience, University of Barcelona, Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.

¹³Department of Psychiatry, Weill Cornell Medicine, NY, USA.

PubMed DOI

Abstract

BACKGROUND: Reliable measurement of mania is essential for therapeutic development in bipolar disorder (BD). The Young Mania Rating Scale (YMRS) remains the most widely used clinician-rated outcome measure for mania in clinical trials. However, variability in scale administration and interpretation across raters and study sites introduces measurement noise and reduces assay sensitivity. This paper…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.